3.0 Disruptive Innovation
in Vaccine Manufacturing
Thomas HessHead- US Commercial June 14th, 2016
Need for 3.0 Disruptive Innovation
• Manufacturing speed always the biggest challenge to meeting EID outbreaks
• Need for 3.0 Technology Platform approach that allows for EID speed of response
• Moving from threat identification to producing a countermeasure is a long and complex process = Need for a faster platform and simplified FDA process.
Introducing the Medicago 3.0 Transient plant-based expression system:
MEDICAGO_FINAL_BILINGUAL.mp4
Introduction to
Medicago
© Medicago Inc.All rights reserved
10
CO
NFI
DEN
TIA
L
Focus Vaccines & Therapeutic Proteins
Manufacturing technology Transient expression in plants
Vaccine technology Virus-like particles
Employees ~300 Expected to grow to 500 by 2019 (commercial)
Success storyInnovative Canadian Vaccine Technology Potential advantages over current vaccine technologies (efficacy, cross protection)Pandemic Supply advantages
Headquarters, laboratories & cGMP facilities
Quebec City, CANADAResearch Triangle Park, NC, USA
Medicago Overview
Our Technology
© Medicago Inc.All rights reserved
12
CO
NFI
DEN
TIA
L
VLPExpress™:A proprietary screening platform for rapidly identifying the best VLP-based antigen target presentations for a disease-causing agentMedicago is using this platform as well to expand identification and development of therapeutic proteins (such as monoclonal antibodies) and biodefense products.
VLPs Vaccine Technology: Virus-Like-Particles (VLPs) are the most exciting emerging vaccine technology for generating effective and long-lasting protection. VLPs mimic the native structure of a virus, allowing them to be recognized readily by the immune system. However, unlike viruses, they lack the core genetic material, making them non-infectious and unable to replicate
Proficia™ technology:A proprietary alternative in manufacturing to current egg-based and cell production systems. The Proficia™ technology is a rapid, flexible, high-yielding and robust vaccine and proteins (such as antibodies) production system.
The benefits of these technologies can make a significant difference for the rapid identification, development and manufacturing of novel vaccines and therapeutic antibodies
Medicago Technologies allow for rapid identification & production of vaccines and therapeutic proteins
Emergency Preparedness
© Medicago Inc.All rights reserved
14
CO
NFI
DEN
TIA
L
To produce different strains of anti-Ebola antibodies, demonstrating the platform’s potential to respond to international emergencies and
pandemics
Medicago’s was awarded two Ebola Contacts in 2015:Collaboration with the US governmentCollaboration with the Canadian Government
© Medicago Inc.All rights reserved
15
CO
NFI
DEN
TIA
L
Avril Mai Juin Juillet Août Septembre Octobre Novembre Décembre0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
First Responder Solution for PandemicsN
umbe
r of f
lu c
ases
wor
ldw
ide
Egg-
base
d va
ccin
es
Vacc
ines
from
Med
icag
o
Identification of strain A/H1N1
First wave begins
Second wave begins
H1N1 PandemicVaccine supply gap
April May June July August September October November December
Vaccine Discovery Program
© Medicago Inc.All rights reserved
17
CO
NFI
DEN
TIA
LVersatile Product Platform: Product pipeline
Research Preclinical Phase I Phase II Phase III
Pandemic
Seasonalquadrivalent
Rotavirus
Human Papilloma Virus
Anti-EbolamAbs
Others mAbs, including
biodefense targets
New vaccine targets
Emergency use
18-6450-64
65+
Questions